As resistance to cisplatin often involves reduced expression/activity of Cu-transporters and/or the volume sensitive osmolyte transporters (VRACs), the emphasis has been on new Pt-based, chemotherapeutic nanocarriers (liposomes, nanoparticles, nanotubes) conjugated with specific ligands (PEG, transferrin, folate) to specifically target tumor cells overexpressing the appropriate receptors. Here, TF is linked to neoplasm.